Tigermed Announces 2026 Interim Results
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting Period"). This document is for information purposes only and is not intended to provide any representation, in whole or in...
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio’s DUPAC Novel-Payload Platform
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises multiple payloads with novel mechanism of action designed to address resistance to the payload classes underlying currently approved ADCs DualityBio to receive a US$45...
Singclean 2nd Leaders Summit Charts New Course in Global Aesthetics
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Hosted within the IMCAS China Conference venue at W Shanghai - The Bund, Singclean 2nd International Medical Aesthetic Leaders Summit themed "Global Vision, Embark on a New Chapter" came to a successful conclusion. 2026 IMCAS China Singclean Highlight Video Gathering top global doctors and industry partners, the summit built a cross-border professional...
Beauty Farm 1H2026 Net Profit Surges 40%, Reinforcing Its Industry Leadership
1H2026 Performance Highlights: Revenue reached RMB1.88 billion, up 29.0% year-on-year Net profit reached RMB240 million, up 40.2% year-on-year Gross profit margin reached 51.4%, up 2.1 percentage points year-on-year Net cash flow generated from operating activities reached RMB550 million, up 34.4% year-on-year HONG KONG, Aug. 28, 2026 /PRNewswire/ -- On August 28, Beauty Farm Medical and Health...
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer’s
HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued orderly development of bispecific antibodies in major chronic disease areas, including...
NECA Expands Telehealth Care with New Counselling and Dietitian Support
NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer. SYDNEY, Aug. 28, 2026 /PRNewswire/ -- NeuroEndocrine Cancer Australia (NECA) has expanded its national telehealth service to include dedicated counselling and dietitian support for the 31,000+ Australians affected by neuroendocrine cancer (NETs), a complex group of cancers that develop from specialised...
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion. The company plans to allocate approximately...
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the "Offering") of (i) American Depositary Shares ("ADSs"),...
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an...
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care
MELBOURNE, Australia, Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer to Australian patients and researchers, reducing the wait for genomic test results that can inform cancer treatment decisions, and accelerating access to personalised treatment and precision diagnostic testing. The...
